- Exchange: OTC US
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Neurologix Inc
+ Add to WatchlistNRGXQ:US
0.0020 USD 0.0009 81.82%As of 20:10:00 ET on 05/17/2013.
Snapshot for Neurologix Inc (NRGXQ)
| Open: | 0.0020 | Day's Range: | 0.0020 - 0.0020 | Volume: | 100,000 |
|---|---|---|---|---|---|
| Previous Close: | 0.0011 | 52wk Range: | 0.0010 - 0.0100 | 1-Yr Rtn: | -33.33% |
Key Statistics for NRGXQ
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2011) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (ttm) | -0.4400 |
| Est. EPS (12/2011) | - |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 0.06 |
| Shares Outstanding (M) | 28.00 |
| 30 Day Average Volume | 8,914 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | - |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for NRGXQ
No data available
Company Profile & Key Executives for NRGXQ
Neurologix, Inc. is developing treatments for disorders of the brain and central nervous system using gene therapy and other alternative therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease and epilepsy. Neurologix's core technology, NLX, is currently being tested in a human clinical trial to treat Parkinson's disease.
| Clark A JohnsonChairman/CEO | Christine V SapanExec VP/Chief Development Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
NRGXQ News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page